Due to Alphamab Oncology's slower growth rate compared to th...

Due to Alphamab Oncology's slower growth rate compared to the industry and notably high P/S ratio, investors may face potential risks. The company's elevated stock price level may not be sustainable in light of its comparatively weak revenue outlook.